GlassScriptPhysician profile
Illia Leibering
NPI 1275201113
$3,086.57
in general payments reported to CMS, 2019-2025
28 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $901 · 2023: $1,423 · 2024: $634 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $378.34 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $302.73 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $255.36 | 2022-2024 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $229.83 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $229.06 | 2022-2024 | Farxiga, Fasenra, Breztri |
| Amgen INC. | $228.42 | 2022-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $189.71 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $137.18 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $103.24 | 2023-2024 | Gemtesa |
| Axsome Therapeutics, INC. | $95.95 | 2023 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $87.73 | 2022 | |
| Organogenesis INC. | $77.57 | 2025 | Puraply Wound Matrix |
| Lundbeck LLC | $75.08 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.40 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.68 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $69.05 | 2022-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $65.29 | 2022-2024 | Xarelto |
| Mylan Specialty L.P. | $64.50 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.59 | 2022 | |
| Idorsia Pharmaceuticals US INC | $52.89 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $49.84 | 2023-2024 | Eliquis |
| Lilly USA, LLC | $46.29 | 2022-2023 | Emgality, Jardiance |
| Otsuka America Pharmaceutical, INC. | $41.09 | 2022-2023 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $38.62 | 2022 | |
| Sunovion Pharmaceuticals INC. | $32.67 | 2022 | |
| Corcept Therapeutics | $16.21 | 2024 | Korlym |
| Horizon Therapeutics Plc | $12.29 | 2022 | |
| Corium, LLC | $3.96 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Illia Leibering listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.